- Shares of Pharmacyclics (PCYC +1.4%) are trading around their 52-week (and all-time) highs.
- Helping the cause is Lazard, where analysts upgraded the shares to Buy from Neutral earlier today.
- Recently: FDA accepts ibrutinib NDA for two B-cell malignancy indications.